Pricing & Access· May 29, 2026 · 10 min readIdvynso (doravirine/islatravir) HIV access guide: the first non-INSTI, tenofovir-free, two-drug regimen — PA criteria, payer coverage, switching protocols, and affordabilityIdvynso (doravirine 100 mg/islatravir 0.25 mg) is Merck's once-daily oral two-drug HIV regimen approved April 21, 2026 as a switch...By Ran Chen#HIV#Infectious Disease#Prior Authorization
